Cambridge, UK and Beijing, China: July 16, 2019 – - Abcam, a global innovator in the field of life science reagents and tools, is pleased to announce today that it will acquire the complete living cell line and cell lysate product portfolio of edigene, a company dedicated to the development of genome editing technology for new therapies and promotion of multiple diseases Innovative solutions for pharmacokinetic development.
With its proprietary high-throughput cell editing platform, Boya has developed the largest existing diploid Library in the industry, covering more than 2800 single gene knockout (KO) cell lines, targeting more than 2600 genes commonly used in human cancer cell lines (including HeLa, hek293-t, A549, HCT116, HepG2 and MCF7).
The existing diploid Ko cell line is an important tool for antibody verification. In addition, it is very important to study and understand biological pathways and disease models, and can be used for screening and cell detection. The cell line and lysate of Boya Zin are widely used by top academic researchers, global biopharmaceutical companies and leading antibody companies.
Commenting on the acquisition, Cheri walker, senior vice president of Abcam enterprise development, said: "we are very excited to be able to bring industry-leading quality and data into the cell line market when we need to conduct antibody research. Cell line market, as a research tool, is in the early stage of development. At this time, if more options are provided and the correct gene target in the correct cell line is used, it will promote the rapid development of the market. "
"We are committed to the development of biotherapy products and high-throughput genome screening service portfolio. Under the guidance of this strategic decision, we are very honored to transfer the complete cell line product portfolio to the Abcam team," commented Dong Wei, chief executive officer of Boya. As an industry recognized leader in providing biological reagents and related tools, we are confident that Abcam will be able to provide expert support to our global user base. "
The lysate series products are expected to be available through the Abcam website at the beginning of Q4 2019, and the expanded cell line products will be available in 2020. In addition, the above products will be used to support further verification of gene knockout antibodies, which is of vital importance for Abcam's ongoing antibody quality program.
About Abcam
As a global life sciences company, Abcam is committed to the discovery, development and sale of high-quality biological reagents and tools, which play an important role in research, drug development and diagnosis. The company works with industry partners to support life scientists to achieve their goals more quickly. With its proprietary development platform and world leading antibody expertise, Abcam has worked with many life science institutions to create innovative biological agents for drug development, in vitro diagnosis and treatment. Through the continuous innovation of biological combination agents and detection kits, Abcam is helping to improve the global understanding of biology and etiology, so as to promote the application of new therapies and the improvement of health status. The company's innovative data sharing approach has increased scientists' confidence in its research results by providing 110000 product validations, user reviews, and peer reviews. With 11 offices around the world, a strong team of 1100 employees from Abcam is located in the world's leading life science research center to further improve its global service and support network.
